Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune SA (NASDAQ: ACIU) announced positive interim results from its Phase 1b/2a study of the anti-pTau Alzheimer's vaccine, demonstrating strong safety and immune responses. The financial update revealed a cash position of CHF 225.9 million, sufficient to sustain operations into Q1 2024. However, contract revenues decreased significantly from CHF 110.5 million in 2019 to CHF 15.4 million in 2020, primarily due to reduced milestone payments. The company anticipates 2021 cash burn between CHF 65 million and CHF 75 million, while further clinical data is expected in Q2.
AC Immune (NASDAQ: ACIU) reported promising Phase 1b results for its novel anti-amyloid-beta vaccine at a global Down syndrome symposium. The vaccine, ACI-24, demonstrated significant immunogenicity and safety, with no serious adverse events recorded. The trial achieved a high retention rate and showed positive pharmacodynamic responses. The company plans to advance the vaccine into mid-stage clinical trials for treating Alzheimer's disease related to Down syndrome, while optimizing its formulation based on encouraging preclinical data.
AC Immune SA (NASDAQ: ACIU) has showcased innovative findings at the AD/PD 2021 conference, focusing on therapies targeting alpha-synuclein and TDP-43, associated with neurodegenerative diseases. Highlights include first-in-class PET tracers and antibody candidates demonstrating significant in vivo actions. The alpha-synuclein program is anticipated to yield first clinical results by Q3 2021, potentially enabling precise disease diagnostics and tailored therapies. With a robust pipeline and strategic collaborations, AC Immune aims to lead in precision medicine for neurodegenerative conditions.
AC Immune (NASDAQ: ACIU) has announced four new data presentations at the upcoming 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM), taking place virtually from March 9–14, 2021. The presentations will focus on preclinical results from the company's therapeutic and diagnostic programs targeting alpha-synuclein and TDP-43. Highlights include two oral presentations on PET imaging agents and therapeutic antibodies, alongside e-posters on small molecule aggregation inhibitors. These advancements underscore AC Immune's commitment to precision medicine in neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. During the event, CEO Prof. Andrea Pfeifer will discuss the company’s precision medicine strategy and the promising interim Phase 1b/2a results of its anti-phospho-Tau vaccine candidate, ACI-35.030, developed in collaboration with Janssen Pharmaceuticals. The results indicated strong immunogenicity and safety in patients with early Alzheimer’s disease. A webcast of the presentation will be available on the company’s website.
AC Immune announced promising interim results from its Phase 1b/2a trial of the ACI-35.030 vaccine for early Alzheimer’s disease. The trial showed 100% of older patients generated high levels of anti-pTau antibodies post-vaccination, significantly exceeding pre-vaccination levels. The vaccine was safe and well-tolerated, with no adverse events reported. The findings support advancing ACI-35.030 into Phase 2/3 trials. This innovation highlights the potential for early intervention in Alzheimer’s, utilizing a cutting-edge vaccine formulation aimed at combating Tau pathology.
AC Immune SA (NASDAQ: ACIU) has initiated a first-in-human study of ACI-12589, a novel PET imaging tracer for Parkinson's disease (PD). This tracer aims to accurately detect pathological alpha-synuclein deposits in the brain, a hallmark of PD. Supported by the Michael J. Fox Foundation, results are expected in Q3 2021. In preclinical studies, ACI-12589 displayed improved sensitivity and specificity compared to previous candidates, potentially leading to earlier diagnosis and effective monitoring of disease progression.
AC Immune SA (NASDAQ: ACIU) announced advancements in its small molecule and antibody therapeutic programs targeting the NLRP3 inflammasome, crucial for neurodegenerative diseases like Alzheimer’s. The company has identified potent small molecule NLRP3 inhibitors, demonstrating significant biological activity in animal models. AC Immune plans to initiate in vivo proof-of-concept studies by year-end to evaluate CNS delivery and efficacy. Additionally, high-affinity antibodies that inhibit ASC-mediated inflammatory responses are under development. These pipeline advancements highlight AC Immune's commitment to addressing neurodegeneration.
AC Immune (NASDAQ: ACIU) received a USD 600,000 grant from Target ALS to advance a collaboration with Massachusetts General Hospital. The funding will accelerate the development of proprietary immuno-assays for detecting TDP-43, a protein linked to several neurodegenerative diseases, including ALS. These assays aim to improve early diagnostics, enabling targeted treatment strategies. AC Immune's CEO highlighted the potential of these assays and the ongoing development of an anti-TDP-43 therapeutic antibody. This positions the company as a leader in precision medicine for neurodegenerative conditions.
AC Immune has announced the appointment of Prof. June as a scientific leader, reinforcing the company's expertise in neurodegeneration. Prof. June is recognized globally for his work in immune tolerance and adoptive immunotherapy. This leadership change aligns with AC Immune's strategy to enhance its research capabilities, particularly in neurodegenerative diseases. The company is expected to leverage his knowledge to advance its pipeline and foster innovation.